Ahola, Aila J.
Harjutsalo, Valma
Thomas, Merlin C.
Forsblom, Carol
Groop, Per-Henrik
Funding for this research was provided by:
Academy of Finland (316664)
Novo Nordisk Fonden (NNF OC0013659)
Signe ja Ane Gyllenbergin Säätiö
Folkhälsanin Tutkimussäätiö
Helsinki University Hospital Research Funds
Wilhelm och Else Stockmanns Stiftelse
Liv och Hälsa Society
Päivikki ja Sakari Sohlbergin Säätiö
Article History
Received: 2 September 2020
Accepted: 16 December 2020
First Online: 15 January 2021
Competing interests
: Professor Per-Henrik Groop has received investigator-initiated grants from Eli Lilly and Roche, is an advisory board member for AbbVie, Astellas, Astra Zeneca, Bayer, Boehringer-Ingelheim, Eli Lilly, Janssen, Medscape, MSD, Mundipharma, Novartis, Novo Nordisk, and Sanofi. He has received lecture honoraria from Astellas, Astra Zeneca, Boehringer-Ingelheim, Eli Lilly, Elo Water, Genzyme, MSD, Novartis, Novo Nordisk, PeerVoice, Sanofi, and Sciarc. All other authors declare no conflicts of interest.